The Commission’s evaluation of the Tobacco Products Directive (TPD) 🎯 substantially overstates its public‑health success and fails to provide a credible evidence base for risk‑proportionate regulation of low‑risk nicotine products.
🔍 Framing & Methodology
• Smoking prevalence reduction is treated as the main success metric, yet the evaluation does not convincingly isolate the TPD’s impact from broader drivers (tax policy, socio‑economic trends, alternative products).
• A 14.3% relative reduction since 2012 is highlighted, but this trajectory is insufficient to reach the EU’s 2040 smoke‑free target.
• The exercise is more of a legislative self‑assessment than a full public‑health impact evaluation, sidelining outcomes like switching to lower‑risk products and unintended illicit market growth.
🛡️ Treatment of Harm Reduction
• Harm reduction is relegated to the margins, framed as “contested” rather than a core pillar of tobacco control.
• All nicotine products are grouped into a homogeneous risk frame, ignoring robust evidence from Sweden & Norway 🇸🇪🇳🇴 where oral low‑risk products have driven very low smoking prevalence.
• Novel products are discussed mainly as “emerging challenges” for youth, rather than as tools to accelerate declines in smoking when regulated proportionately.
đź“Š Evidence Use & Bias
• Selective evidence use: risks of alternatives are amplified, while real‑world switching data and comparative risk assessments are under‑represented.
• Longitudinal data showing vaping and other non‑combustibles displacing smoking is downplayed.
• Instead of structured risk tiers, the evaluation leans toward broad harmonisation that risks levelling low‑risk products up to cigarette burdens.
⚖️ Policy Implications
The evaluation supports extensions of the current TPD model (larger warnings, plain packaging, tighter restrictions). From a GINN perspective, this is problematic because:
• ❌ Encourages flavour bans & severe packaging restrictions that harm adult switching.
• ❌ Paves the way for fiscal/regulatory equalisation between combustibles & low‑risk products.
• ❌ Risks expanding illicit markets and cross‑border purchasing.
âś… GINN Recommendations for TPD Revision
A credible, future‑proof TPD should be anchored in measurable reductions in smoking‑related disease & death:
• Embed risk‑proportionate regulation with clear product categories & tax tiers.
• Protect adult access to appealing low‑risk alternatives (flavours, competitive pricing) while deploying strict, evidence‑based youth safeguards.
• Use real‑world harm‑reduction data from successful Member States to guide EU rules, not penalise them in the name of harmonisation.
🚨 Without this course correction, TPD3 risks missing the EU’s smoke‑free objectives, entrenching cigarette dominance, and losing one of Europe’s greatest public‑health opportunities.
